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Abstract An analytical assay has been developed and
validated for ultrafast and high-throughput mass spectro-
metric determination of pemetrexed concentrations in
plasma using matrix assisted laser desorption/ionization–
triple quadrupole–tandem mass spectrometry. Patient plas-
ma samples spiked with the internal standard methotrexate
were measured by multiple reaction monitoring. The
detection limit was 0.4 fmol/μL, lower limit of quantifica-
tion was 0.9 fmol/μL, and upper limit of quantification was
60 fmol/μL, respectively. Overall observed pemetrexed
concentrations in patient samples ranged between 8.7 (1.4)
and 142.7 (20.3)pmol/μL (SD). The newly developed mass
spectrometric assay is applicable for (routine) therapeutic
drug monitoring of pemetrexed concentrations in plasma
from non-small cell lung cancer patients.
Keywords Pemetrexed.NSCLC.MALDI-QqQ-MS/MS.
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Introduction
Pemetrexed (PTX) (Alimta®; N-[4-[2-[2-Amino-4,7-dihy-
dro-4-oxy-3H-pyrrolo[2,3-d]pyrimidine-5-yl ethyl] benzo-
yl]-L-glutamic acid]; Fig. 1a) is a multi-targeted anti-folate
drug applied in the treatment of malignant pleural meso-
thelioma and non-small cell lung cancer (NSCLC) [1].
Therapeutic drug plasma concentrations are defined for
various types of drugs, offering a useful tool for monitoring
drug dosage and avoiding drug toxicity and obtain
therapeutic efficacy. PTX plasma concentrations can be
determined by (high-performance) liquid chromatography
with ultraviolet (HPLC-UV) [2–4] or mass spectrometric
detection (LC-MS) [5]. HPLC-UVand LC-MS methods are
time-consuming and less suitable for routine measurement
of many samples.
To avoid long analysis time, we applied matrix assisted
laser desorption/ionization–triple quadrupole–tandem mass
spectrometry (MALDI-QqQ-MS/MS) for the development
of a new assay. MALDI-QqQ-MS/MS does not require
liquid chromatographic separation prior to analyses and
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and is therefore very suitable for the analysis of many
samples in a short time. The MALDI-QqQ-MS/MS
technology has been used previously for the determination
of drug concentrations [6–9] and for enzyme inhibition
studies [10].
Here, we report a new ultrafast and high-throughput
MALDI-QqQ-MS/MS assay for therapeutic drug monitor-
ing of pemetrexed concentrations in plasma from NSCLC
patients.
Methods and materials
Chemicals
Pemetrexed (Alimta®; N-[4-[2-[2-Amino-4,7-dihydro-4-
oxy-3H-pyrrolo[2,3-d]pyrimidine-5-yl ethyl]benzoyl]-L-
glutamic acid disodium salt heptahydrate]) was obtained
from the Department of Pharmacy, Erasmus MC and
methotrexate (4-amino-10-methylpteroylglutamic acid,
MTX) used as internal standard was from Schircks
Laboratories (Jona, Switzerland). Solvents were of LC-MS
grade (Biosolve, Valkenswaard, the Netherlands) and other
chemicals were from ACS grade (Sigma Aldrich,
Zwijndrecht, the Netherlands).
Preparation of plasma matrix-based calibrators
and calibration curve
Standard stock solution (PTX, 600 nmol/L and MTX,
550 nmol/L) were prepared in LC-MS quality water. PTX
plasma matrix-based calibrators were prepared by dilution
with drug-free human control plasma (Sanquin Blood
Supply Foundation, Rotterdam, the Netherlands) to yield
following calibrators: 60, 30, 15, 7.5, 3.75, 1.88, and
0.94 pmol/μL. Ten microliter of the calibrators were
pipetted into 10 mL volumetric flasks and simultaneously
deproteinized/diluted (1:1,000) with an acetonitrile/water
(60/40% v/v) mixture. Calibrators were centrifuged (5 min
at 2,000×g) and 20 μL of supernatant were mixed with α-
CHCA (10 μL, 6.2 mg/mL in methanol/acetonitrile/water
36/56/8% (v/v/v), pH=2.5) matrix solution and 1.5 μL were
spotted (n=3, 10 spots per quality control (QC) sample) on
a Opti-TOF 96-well stainless steel target plate (123×
81 mm; MDS Analytical Technologies, Concord, Canada)
and spots were dried at room temperature (5 min).
MALDI-QqQ-MS/MS instrumentation
Analyses were conducted by a Flashquant Workstation with
a 4000 API mass analyzer (MDS Analytical Technologies,
Concord, Canada) operating in the positive ionization
Fig. 1 Example of ultrafast and high-throughput MALDI-QqQ-MS/
MS analyses. Illustrated are reconstructed MRM traces of Pemetrexed
(black) and internal standard methotrexate (red) from a QC sample-
containing pemetrexed at a concentration level of 30 fmol/μL.
Chemical structure of a pemetrexed and b methotrexate and respective
fragmentation and MRM transitions
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8 arbitrary units, source gas 10 arbitrary units, dwell time
20 ms, plate voltage 45 V, laser power 45% and laser raster
speed 1 mm/s. Instrument control/data analyses were
performed using Flashquant 1.0 and Analyst 1.4.2 applica-
tion software. Different MALDI matrices such as 2,5-
dihydroxy benzoic acid (2,5-DHB), 7-hydroxy-4-(trifluor-
omethyl)-coumarin (HFMC) [11] and α-cyano-hydroxy-
cinnamic acid (α-CHCA) were used to determine the
highest possible sensitivity. Therefore, 10 μL of a PTX/
MTX solution (approx. 100 nmol/L) were mixed with all
MALDI matrices (10 μL) and analyzed in positive full scan
mode (m/z=150 to m/z=350).
Assay validation
Validated assay parameters according to FDA guidelines
[12] were: limit of detection (LOD), lower limit of
quantification (LLOQ), linearity, accuracy, precision, re-
covery and stability of PTX using QC samples prepared in
drug-free human control plasma at 6.0, 30.0, and
60.0 pmol/μL.
Preparation of patient samples
EDTA-blood was collected (1 week after admission) from
patients who had received one dose of PTX (500 mg/m
2)a n d
who have written consent for using their blood samples.
Plasma was prepared by centrifugation for 10 min (4 °C,
1,400×g). Ten microliters of plasma were transferred into a
10.00 mL volumetric flask and spiked with 10 μLM T X
(27.5 μmol/L) and deproteinized/diluted with an acetonitrile/
water mixture (60/40% v/v). Precipitated proteins were
removed by centrifugation (5 min at 2,000×g)a ta m b i e n t
temperature and 20 μL supernatant were mixed with
MALDI matrix (10 μL) and 1.5 μLw e r es p o t t e d( n=10).
Results
MALDI-QqQ-MS/MS analysis
From all matrices, α-CHCA matrix gave the highest signal
intensity for PTX and MTX. Protonated ions of PTX and
MTX ((MH)
+) were m/z=428.2 for PTX and m/z=455.2 for
MTX. These protonated ions were used for further assay
optimization. Optimized instrument parameters were: colli-
sion energy 38 and 25 V and collision cell energy exit
potential 13 and 10 V for PTX and MTX, respectively.
Collision-induced dissociation resulted in the formation of
protonated fragment ions (Fig. 1). Selected MRM transi-
tions were for PTX m/z=428.2>281.2 and for MTX m/z=
455.2>308.2.
Assay validation
Analyte recovery
To avoid laborious sample preparations by SPE or
extraction, we tried to isolate PTX from plasma by
deproteinization with trichloroacetic acid (TCA). We
determined recoveries using QC samples (30 pmol/μL)
deproteinized with different TCA concentrations; 5%,
10%, 20% and 30% TCA (% w/v). Recoveries ranged
between 13% and 30% for PTX and between 20% and
62% for MTX. To obtain probably higher recoveries, we
transferred 100 μL aliquots of the supernatant of QC
sample (10% TCA) onto a 96-well SPE method develop-
ment plate (25 mg/well; Sigma Aldrich, Zwijndrecht, the
Netherlands). Recovery rates on following SPE adsorb-
ents; PS/PVB (polysterene divinyl benzene), octadecyl
(C18), octyl (C8), cyanopropyl, MCAX (mixed-mode
strong cation exchange), and WCX (weak cation ex-
change) were determined. Conditioning of the wells was
done by acetone (2×1 mL), methanol (2×1 mL), and
water (2×1 mL) except for WCX/SAX the last condition-
i n gs t e pu s e dw a s2 × 1m LH 2O/10% TCA (% w/v).
Extraction was done by 100 μL of methanol, 20 μLo ft h e
extract was mixed with α-CHCA (10 μL) and 1.5 μLw e r e
spotted (n=10). Recoveries were still low (<60%).
Because of the low recoveries, we decided to just
deproteinize the QC samples by addition of acetonitrile/
water mixtures. Ten microliters were deproteinized/diluted
(1:1,000)withdifferentacetonitrile/watermixtures;40/60,50/
50 and 60/40% (v/v). The highest recoveries were obtained
for 60:40% (v/v) acetonitrile/water mixture; PTX (91%) and
MTX (80%), while recovery rates dropped to 61% and 66%
and 58% and 69% for PTX and MTX if we used 50/50% (v/
v) and 40/60% (v/v) mixtures, respectively.
Linearity
The selected matrix-based calibrators (0.94–60 pmol/μL)
displayed a linear relationship between MRM peak area and
PTX concentration (r
2=0.9973, y=101.96x+84.245). Linear
regression of the results was done using GraphPad Prism
version 5.00 (GraphPad Software, San Diego, CA, USA).
LLOQ and LOD
The LLOQ was defined as the lowest calibrator of the
calibration curve that could be analyzed with an accuracy
and precision of CV <20% [12]. The LLOQ of PTX was
0.94 pmol/μL and upper limit of quantification was
60 fmol/μL (CV <15%). The LOD of PTX, defined at a
signal-to-noise ratio of (3:1) in drug-free human control
plasma, was 0.4 fmol/μL.
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The accuracy and precision were within FDA criteria (CV
<15%) at all three validation levels (Table 1), precision
expressed as% CV was between 11.9% and 31.8% for
within-run and between 8.5% and 14.5% for between-run
experiments. Accuracy expressed as% RSD ranged be-
tween 2.5% and 5.7% for within-run and between 1.7% and
6.0% for between-run experiments.
PTX stability
PTX, according to FDA criteria, is defined as stable when
the concentration decrease in plasma matrix was <15%
(expressed as % error). This was the case at all three QC
validation levels (Table 1).
Application of assay to patient samples
Observed PTX plasma concentrations in analyzed patient
samples are presented in Table 2. Results show that patient A
has an increased plasma concentration of PTX after the
second administration compared to first administration,
patient C though showed no increased plasma concentration
level after the second administration. Other patients (B, D, E,
F, and G) had received their first administration of PTX at
the moment the samples were collected.
Discussion
Recently, it was demonstrated that MALDI-QqQ-MS/MS is
an ultrafast, high-throughput and sensitive mass spectro-
metric technique [7 ,8, 13–16] for small molecules.
Analysis times for pemetrexed on HPLC- or LC-MS
instrumentations are between 7 and 20 min [3, 5, 17] per
sample measured by HPLC and up to 30 min per sample for
Table 1 Precision and accuracy and stability experiments of developed assay at three different plasma concentration levels (n=3)
Analyte Pemetrexed Storage Conditions/Time
a
Within-run validation
a Between-run validation
b Refrigerator (4 °C) Freezer (−20 °C) Freezer (−20 °C)
24 h 20 days 3 freeze/thaw cycles
Mean (SD) %Error
c Mean (SD) %Error
c Mean (SD) %Error
c
Nominal concentration
(pmol/μL)
6.0 30.0 60.0 6.0 30.0 60.0
Mean observed
concentration (pmol/μL)
6.2 31.7 58.5 5.9 31.8 62.2
Accuracy (% RSD
d) 3.3 5.7 2.5 1.7 6.0 3.7
Precision (% CV) 12.9 13.8 11.9 13.7 14.5 8.5
Nominal concentration
(pmol/μL)
60.0 62.8 (6.0) 4.7 59.3 (5.8) −1.2 58.7 (4.9) −2.2
30.0 29.5 (3.8) −1.7 31.5 (3.9) 5.0 29.2 (2.7) −2.7
6.0 6.5 (1.2) 8.3 6.2 (0.8) 3.3 5.9 (0.5) −1.7
aResults summarize ten spots per QC sample at each concentration level in one experiment
bResults summarize three different experiments from three consecutive days with 10 spots per QC sample at each concentration level
c%Error=(mean observed concentration−nominal concentration)/(nominal concentration)×100%
dRSD, relative standard deviation of the mean observed concentration
Table 2 Measured pemetrexed concentrations in plasma from
NSCLC patients (n=3)
Patient code Pemetrexed concentration
(pmol/μL)
a mean (SD)
Gender
b Age
A 80.0 (9.3) f 51
A 142.7 (20.3)
c f5 1
B 8.7 (1.4) f 56
C 63.0 (7.0) m 66
C 60.7 (8.3)
c m6 6
D 33.3 (4.9) m 75
E 42.7 (9.7) m 48
F 49.1 (10.8) f 56
G 121.0 (20.2) m 61
aResults summarize 10 spots per patient sample
bFemale (f) and male (m)
cSecond administration of 500 mg/m
2, 3 weeks after first administration
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analysis time of approx. 10 s per sample (Fig. 1).
Figure 1 illustrates that multiple measurement of a
plasma sample (n=24) can be accomplished within 4 min
with acceptable accuracy (CV 13.1%).
Some papers [2, 3, 5, 18] report the measurement of PTX
in plasma and many papers use SPE. Hamilton et al. [3]
reported recoveries for PTX depending on the PTX
concentration, at a concentration of 15 ng/mL (35 fmol/
μL), recoveries were 40% and at 1,200 ng/mL (2,760 fmol/
μL) the recovery was 83%. Higher recoveries were reported
by [2]( 7 6 . 9 % ) ,w h i l e[ 5] reported recoveries of 99% and
124%. We studied also SPE but obtained only low recoveries
for PTX and MTX. Instead, we tested different acetonitrile/
water mixtures for PTX and MTX isolation from proteins in
plasma. Due to expected PTX patient plasma concentrations
in the micro molar range, simultaneous deproteinization and
dilution (1:1,000) of patient plasma samples were studied.
The highest analyte recoveries were obtained with an
acetonitrile/water (60:40% v/v) mixture; recoveries were
91% for PTX and 80% for MTX, respectively.
The LOD of the assay is 0.4 fmol/μL, significantly lower
than previously reported LODs of 23 fmol/μL and 6 fmol/
μL[ 3–5], respectively.
The assay had been validated by the determination of
linearity, recovery rates, within- and between-run accuracy
and precision and stability of PTX. The within- and
between-run accuracy and precision as well as stability of
PTX were all <15% CV and are in good compliance with
the FDA regulation [12] (Table 1).
The total plasma amount spotted is 0.001 μL while
others [5] injected in total 3.5 μL of plasma into the LC-MS
system, demonstrating the very high sensitivity of the assay.
After the validation, the assay was applied to NSCLC
patient samples. PTX concentrations ranged between 8.7
(1.4) and 142.7 (20.3)pmol/μL (SD). Two patients had
already received a second dose (Table 2). One of the two
patients showed a significant increase (142.7 (20.3)pmol/
μL) compared to the first dose (80.0 (9.3)pmol/μL). This
significant increase of the PTX plasma concentration
cannot be explained by an increasing steady-state plasma
concentration level between two administrations, since the
half-life time of PTX is 3.5 h [19]. More experiments/
studies will be necessary to determine pharmacokinetic
properties for extra- and intracellular concentrations of PTX
to be able to understand significant increased plasma
concentration levels in patients.
Conclusion
Wehave developed an ultrafast,sensitive, and high-throughput
assay for the determination of PTX concentrations in plasma
from NSCLC patients. The assay can be used for therapeutic
drug monitoring of PTX plasma concentration levels and the
assay is so sensitivethat it can support pharmacokinetic studies
even with plasma amounts of few microliters.
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